553 completed, 142 unknown, 112 recruiting, 107 active not recruiting. 554 Phase 2, 320 Phase 3, 206 Phase 1, 44 Not applicable, 32 Phase 4.
Follow Vincristine: new trials by email Literature Review of Vincristine trials Research Report on Vincristine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Asciminib, Biospecimen Collection, Blinatumomab - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 21 | 2027-10-13 | 2026-11-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-12-30 | 2026-11-06 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 3 | Not yet recruiting | AstraZeneca | 1200 | 2026-12-22 | 2026-11-02 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-12-01 | 2026-11-06 |
| Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL Inotuzumab ozogamicin (INO), Venetoclax (VEN), Vincristine - ALL | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2026-11-30 | 2026-11-06 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Recruiting | AIDS Malignancy Consortium | 43 | 2026-09-16 | 2026-11-17 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-11-19 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-11-12 |
| A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) Ifupinostat Hydrochloride for Injection, Cyclophosphamide for Injection, Doxorubicin Hydrochloride for Injection - Previously Untreated Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | BeBetter Med Inc | 120 | 2026-07-01 | 2026-06-30 |
| A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Orelabrutinib, obinutuzumab, Lenalidomide - Follicular Lymphoma ( FL) | Phase 3 | Not yet recruiting | Ruijin Hospital | 652 | 2026-07-01 | 2026-07-22 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-11-13 |
| A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation Epcoritamab, Pirtobrutinib, Cyclophosphamide - Richter Transformation | Phase 2 | Recruiting | German CLL Study Group | 116 | 2026-06-18 | 2026-11-19 |
Showing 20 of 1064. Sign in to see all of them.
Lymphoma (218) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (192) · Lymphoma, Large B-Cell, Diffuse (177) · Leukemia (102) · Burkitt Lymphoma (94) · Lymphoma, Non-Hodgkin (92) · Lymphoma, Follicular (81) · Lymphoma, Mantle-Cell (53) · Neuroblastoma (51) · Hodgkin Disease (46) · Central Nervous System Neoplasms (43) · Sarcoma (37) · Lymphoma, B-Cell (32) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (31) · Lymphoma, Large-Cell, Anaplastic (29)
Children's Oncology Group (109) · National Cancer Institute (NCI) (89) · M.D. Anderson Cancer Center (56) · St. Jude Children's Research Hospital (36) · Memorial Sloan Kettering Cancer Center (25) · SWOG Cancer Research Network (20) · Children's Cancer and Leukaemia Group (17) · Alliance for Clinical Trials in Oncology (16) · Hoffmann-La Roche (16) · Sun Yat-sen University (15) · Institute of Hematology & Blood Diseases Hospital, China (14) · Dana-Farber Cancer Institute (12) · European Organisation for Research and Treatment of Cancer - EORTC (12) · PETHEMA Foundation (12) · Ruijin Hospital (12)
United States (636) · Canada (179) · Australia (155) · United Kingdom (124) · China (121) · Germany (111) · France (110) · Italy (103) · Spain (88) · Switzerland (87) · Puerto Rico (83) · Netherlands (74) · Belgium (69) · New Zealand (65) · Poland (53)
Elias Jabbour (8) · Amar Gajjar, MD (6) · Oliver W. Press, MD, PhD (6) · Sima Jeha, MD (6) · Frank Berthold, MD (5) · Lode J. Swinnen, MD (5) · Sandra J. Horning, MD (5) · Ann Barrett (4) · Dieter Hoelzer, MD,PhD (4) · Dieter Koerholz, MD (4)
PMID 41671463, PMID 37505794, PMID 39121442, PMID 40135712, PMID 35622074, PMID 39319495, PMID 37890117, PMID 38446568, PMID 38603649, PMID 23007406, PMID 24970932, PMID 33242441, PMID 34048072, PMID 35882475, PMID 39058968, PMID 16105981, PMID 16421426, PMID 16754935, PMID 17654614, PMID 19144982, PMID 19433688, PMID 19546402, PMID 20007997, PMID 20032498, PMID 20154213, PMID 20548096, PMID 20567002, PMID 20661232, PMID 21719599, PMID 22337718, PMID 22442346, PMID 22493293, PMID 22689675, PMID 23024237, PMID 23233662, PMID 24224624, PMID 24344215, PMID 24687837, PMID 25135998, PMID 26590194, PMID 26888258, PMID 26913693, PMID 27282998, PMID 27465021, PMID 27561722, PMID 28751559, PMID 29148893, PMID 29284596, PMID 30010775, PMID 30125215
U10CA180886 (57), U10CA098543 (52), U10CA032102 (22), 2023 (12), U10CA021115 (11), U10CA031946 (10), U10CA180888 (9), 2015 (8), U10CA180821 (7), 2017 (6), P30CA016672 (6), UM1CA121947 (6), 2018 (5), P30CA033572 (5), P30CA036727 (5)